Skip to main content

Table 5 Documented complication during hospitalization after adjusting for baseline covariates

From: Clinical characteristics and outcomes of critically ill mechanically ventilated COVID-19 patients receiving interleukin-6 receptor antagonists and corticosteroid therapy: a preliminary report from a multinational registry

Variables Steroids IL6-RAs Both p
Na 804.1 582.4 689.6  
None 35 (4.3) 40 (6.8) 16 (2.3) 0.30
Acute cardiac injury 63 (7.9) 56 (9.6) 33 (4.8) 0.32
Acute kidney injury 292 (36.4) 280 (48.1) 277 (40.2) 0.15
Cardiac arrest 155 (19.3) 84 (14.4) 114 (16.5) 0.52
Cardiac arrhythmia new onset 101 (12.6) 67 (11.4) 66 (9.6) 0.72
Coagulation disorder disseminated intravascular coagulation 34 (4.3) 59 (10.0) 50 (7.3) 0.23
Deep vein thrombosis 51 (6.3) 59 (10.1) 68 ( 9.9) 0.34
Empyema 3 (0.3) 5 (0.9) 5 (0.7) 0.70
High troponin level 97 (12.1) 57 (9.8) 134 (19.4) 0.04
Liver dysfunction/acute liver failure 118 (14.6) 139 (23.9) 82 (11.9) 0.04
Lung abscesses 3 (0.3) 0 (0) 5 (0.7) 0.45
Myocarditis 8 (1.0) 7 (1.3) 0 (0) 0.28
Pneumothorax 54 (6.8) 35 (6.0) 30 (4.4) 0.64
Causative microbiology and rate of secondary infections
 Respiratory viral panel (RVP) PCR positiveb 1 (0.2) 2 (1.2) 0 (0) 0.72
 Bacterial pneumonia 192 (23.9) 173 (29.7) 197 (28.5) 0.46
 Cytomegalovirus PCR positive 2 (0.3) 0 (0) 1 (0.9) 0.40
 Legionella urine Ag positive 0 (0) 1 (0.6) 0 (0) 0.32
 Blood cultures positivec 93 (21.9) 27 (17.2) 17 (19.3) 0.44
 Hospital day(s) positive blood cultures performed, median [IQR] 7 [0.25; 14] 14 [1; 22] 10 [0.75; 13] 0.14
 Sputum culture positived 167 (50.6) 65 (53.3) 34 (45.9) 0.61
 Hospital day(s) positive sputum culture performed, median [IQR] 4 [1; 11] 5 [1.5; 9] 5 [1; 13.5] 0.87
 Urine culture positivee 74 (29.2) 23 (20.2) 11 (19.6) 0.10
  1. Data presented as n (%) unless otherwise specified
  2. IL6-RAs interleukin-6 receptor antagonists
  3. aEach individual gets its own weight that is used for further analysis. Multiplication by these weights can usually results in decimals
  4. bPerformed in 127 individuals in steroids group, 85 in IL6-RAs group, 33 in combination group
  5. cPerformed in 424 individuals in steroids group, 157 in IL6-RAs group, 88 in combination group
  6. dPerformed in 331 individuals in steroids group, 121 in IL6-RAs group, 74 in combination group
  7. ePerformed in 254 individuals in steroids group, 114 in IL6-RAs group, 56 in combination group
  8. Bold values indicate a significant value at 5% level of significance